Compass Therapeutics, Inc. Board of Directors

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Dr. James Kranz Ph.D.

Dr. James Kranz Ph.D.

VP and Head of Chemistry Manufacturing & Controls

Ms. Karin Herrera B.A.

Ms. Karin Herrera B.A.

VP & Head of Clinical Operations

Anna Gifford

Anna Gifford

Communications Manager

Mr. Jonathan Anderman J.D.

Mr. Jonathan Anderman J.D.

VP, Head of Legal & Corporate Secretary

Dr. Minori Rosales M.D., Ph.D.

Dr. Minori Rosales M.D., Ph.D.

Senior VP & Head of Clinical Development

Mr. Barry Shin J.D.

Mr. Barry Shin J.D.

Chief Financial Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.